Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
THANK YOU FOR SUBSCRIBING
Ventripoint Diagnostics: Game-Changing Alternative to Conventional Heart Scans
Follow Ventripoint Diagnostics on :
Dr. George Adams, Chairman of the Board and CEO, Ventripoint Diagnostics
The effective treatment of congenital heart disease requires determining the size, functioning, and accurate measurement of all four cardiac chambers. However, due to the complex shape of the right ventricle (RV) and the position in the chest cavity, it is hard for doctors to get a clear image even with modern day ultrasound equipment. The poor image quality makes the effective analysis and treatment of congenital heart disease challenging. These challenges are worsened by the fact that most children born with congenital heart disease have RV defects.
Bridging this gap with its VMS+ software that can simplify and enhance the detection of congenital heart defects is Ventripoint Diagnostics. The firm’s ‘first-of-its-kind’ diagnostic software develops an accurate 3D model of a heart using 2D ultrasound scans. The software enables clinicians to obtain cardiac metrics on all heart chambers within minutes, even if the scans are of poor quality (i.e. dropout, lack of visibility of endocardial borders, etc.). VMS+ is powered by Ventripoint Diagnostics’ knowledge-based reconstruction (KBR) algorithm, which leverages a database of previously defined heart images and anatomical landmarks from standard 2D echo images to construct a complete 3D model with a precision equivalent to MRI.
“We can obtain accurate and trustworthy findings for the right ventricle and right atrium using our AI-driven KBR algorithm that achieves accuracy at a scale not seen before,” says Dr. George Adams, Chairman of the Board and CEO of Ventripoint Diagnostics.
The company is paving the way for the effective treatment of Tetralogy of Fallot (ToF), the most common cyanotic congenital cardiac condition detected in infants and young children. Treating the disease has been a persistent challenge in the healthcare sector for years because clinicians struggle to identify the optimal point to surgically fix the RV pulmonary valve. If the surgery is performed early, the patient will require a reoperation and runs out of opportunities to receive reconstructive procedures, but when intervened too late, the right ventricle becomes too enlarged and when the new pulmonary valve is put in, the patient’s right ventricle will not be able to recover properly. VMS+ simplifies the treatment of ToF by measuring RV volumes repeatedly for faster quantification of ventricular size, volume, and function, thereby enabling practitioners to track the progression of the pulmonary valve and perform a timely replacement.
We can obtain accurate and trustworthy findings for the right ventricle and right atrium using our AI-driven KBR algorithm that achieves accuracy at a scale not seen before
Ventripoint Diagnostics also resolves the requirement of general anesthesia in pediatric cardiac scans. Cardiac MRI requires the patient to remain motionless, which is difficult to achieve in toddlers without sedation. VMS+ is a more childfriendly experience than an MRI as it does not require the patient to be still for long periods. A real-world scenario highlighting the company’s competency in enhancing patient experiences is that of a pediatric cardiologist that has been a long-time user of the system. He could quickly scan a two-year-old patient using VMS+ while improving the overall patient experience by making it easier for the child’s parents to be present during the scan.
The third iteration of the software, VMS+ 3.0, is a vendor neutral diagnostic aid that seamlessly integrates into a clinic or hospital infrastructure and works with echo images generated by any ultrasound device. Ventripoint Diagnostics’ inventive approach offers patients a superior diagnostic alternative while giving medical professionals the equipment to conduct precise scans and transform patient care.
Management Dr. George Adams, Chairman of the Board and CEO, Ventripoint Diagnostics
Description Ventripoint Diagnostics is the only company in the world that is able to take 2D ultrasound scans of the heart and create reliable 3D renditions using its VMS+ software. The VMS+ fills a void in the ability to assess a heart quickly using conventional 2D alternatives.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: